Dr. Manuel Alós Almiñana
Principal Investigator
Clinical Associated Group in Pharmacy
Presentation
Publications
Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients. Garcia-Molina A, Alos-Alminana M. Farmacia Hospitalaria. 2023 Jan-Feb;47(1):10-15. doi: 10.1016/j.farma.2022.12.003. PMID: 36635189
Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients. Garcia-Molina A, Alos-Alminana M. Farmacia Hospitalaria. 2023 Jan-Feb;47(1):T10-T15. doi: 10.1016/j.farma.2022.12.014. PMID: 36707309
Validated HPLC-UV method for amphotericin B quantification in a critical patient receiving AmBisome and treated with extracorporeal replacement therapies. Ezquer-Garin C, Aguilar G, Ferriols-Lisart R, Alos-Alminana M. Biomedical Chromatography. 2023 Dec;37(12):e5749. doi: 10.1002/bmc.5749. PMID: 37727118
The usefulness of in vitro percutaneous absorption experiments applying the infinite dose technique to predict in vivo plasma levels: comparison of model-predicted and observed plasma concentrations of nortriptyline in rats. Usach I, Di Marco S, Diez O, Alos M, Peris J. Pharmaceutics. 2022 Jul 12;14(7):1457. doi: 10.3390/pharmaceutics14071457. PMID: 35890351
Health outcomes and primary adherence to secondary prevention treatment after st-elevation myocardial infarction: a spanish cohort study. Lopez A, Alos Almiñana M, Peris J. Journal of Cardiovascular Translational Research. 2021 Apr;14(2):308-316. doi: 10.1007/s12265-020-10045-0. PMID: 32557320
+ Info
Title: Evaluaciónn económica en la práctica asistencial del tratamiento del virus de la hepatitis c basado en antivirales de acción directa
Doctoral candidate: Pardillo Armuña, Raquel
Director(s): Alós Almiñana, Manuel; D’ocon Navaza, Pilar; Ferriols Lisart, Rafael
Date of the defense: 21/11/2022
University: Universitat de València
Doctoral candidate: Pardillo Armuña, Raquel
Director(s): Alós Almiñana, Manuel; D’ocon Navaza, Pilar; Ferriols Lisart, Rafael
Date of the defense: 21/11/2022
University: Universitat de València